NPRA Banner

               
Product Search   QUEST3+ System   Enquiries   Sitemap  

MOPI: Quality Assurance and GMP Training Program 2025

User Rating: 5 / 5

Star ActiveStar ActiveStar ActiveStar ActiveStar Active
 

The training program consists of 5 on-line courses and 9 physical courses. These courses cover the essential principles of Quality Assurance (QA), Good Manufacturing Practice (GMP), Validations, Supply chain Management, Medical Devices etc. Participants are expected to gain an understanding of current requirements and future international trends within the regulated industry. The courses consist of a lively combination of case study workshops and group presentation. The training has been adapted for delivery in an online, virtual classroom and physical training.

Aims and Objectives

The aim of the training program is to provide conceptual understanding of GMP, as well as to introduce the various current practices for implementation at the workplace.

Who Should Attend?

Key personnel in GMP & Quality Management, Managers, Engineers, Executives, Quality Practitioners, and any member of the pharmaceutical and related industry. Those from Research and Development, Quality and Production will find this program relevant and beneficial to their job function as well.

 

BOOK YOUR SEAT NOW!!!

For further enquiries, please contact:

Mike, Malaysian Organisation of Pharmaceutical Industries,

Global Business & Convention Centre,

Mezzanine Floor, Block A, No. 8, Jalan 19/1, Section 19,

46300 Petaling Jaya, Selangoer, West Malaysia

Tel: 03-7931 9003 Fax: 03-7932 2730

E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. and This email address is being protected from spambots. You need JavaScript enabled to view it.

www.mopi.org.my

 

CLICK HERE FOR TRAINING BROCHURE

 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Friday 20 December 2024, 19:30:56.

Search

Main Menu English